BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,221
Employees3,221
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,221
Employees3,221

BMRN Key Statistics

Market cap
10.69B
Market cap10.69B
Price-Earnings ratio
29.97
Price-Earnings ratio29.97
Dividend yield
Dividend yield
Average volume
2.28M
Average volume2.28M
High today
$56.25
High today$56.25
Low today
$54.61
Low today$54.61
Open price
$54.61
Open price$54.61
Volume
1.95M
Volume1.95M
52 Week high
$73.18
52 Week high$73.18
52 Week low
$50.76
52 Week low$50.76

Stock Snapshot

With a market cap of 10.69B, BioMarin(BMRN) trades at $56.25. The stock has a price-to-earnings ratio of 29.97.

On 2026-03-25, BioMarin(BMRN) stock moved within a range of $54.61 to $56.25. With shares now at $56.25, the stock is trading +3.0% above its intraday low and 0.0% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 1.95M, versus its average volume of 2.28M.

Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.18 and a low of $50.76.

Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.18 and a low of $50.76.

BMRN News

Simply Wall St 2d
Did VOXZOGO Trial Pauses After Hip Events Just Shift BioMarin Pharmaceutical's Investment Narrative?

Earlier in March 2026, BioMarin Pharmaceutical halted dosing and enrollment in Phase 2 VOXZOGO trials for Turner syndrome, SHOX-deficiency and ACAN-deficiency a...

Did VOXZOGO Trial Pauses After Hip Events Just Shift BioMarin Pharmaceutical's Investment Narrative?

Analyst ratings

81%

of 26 ratings
Buy
80.8%
Hold
19.2%
Sell
0%

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.